These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17074449)

  • 1. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.
    Medina KL; Shear PK
    Drug Alcohol Depend; 2007 Mar; 87(2-3):303-11. PubMed ID: 17074449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
    Bedi G; Van Dam NT; Redman J
    J Psychopharmacol; 2010 Feb; 24(2):233-40. PubMed ID: 18832429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
    Taurah L; Chandler C; Sanders G
    Psychopharmacology (Berl); 2014 Feb; 231(4):737-51. PubMed ID: 24114426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reports of executive dysfunction in current ecstasy/polydrug Users.
    Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
    Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity.
    Morgan MJ
    Neuropsychopharmacology; 1998 Oct; 19(4):252-64. PubMed ID: 9718589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depressive and anxiety symptomatology in ecstasy users: the relative contribution of genes, trauma, life stress and drug use.
    Scott RM; Hides L; Allen JS; Burke R; Lubman DI
    Psychopharmacology (Berl); 2010 Mar; 209(1):25-36. PubMed ID: 20101393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
    Parrott AC; Milani RM; Parmar R; Turner JD
    Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological evidence of atypical processing underlying mental set shifting in ecstasy polydrug and polydrug users.
    Roberts CA; Fairclough SH; McGlone FP; Fisk JE; Montgomery C
    Exp Clin Psychopharmacol; 2013 Dec; 21(6):507-15. PubMed ID: 24080019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.
    Wetherell MA; Montgomery C
    Psychopharmacology (Berl); 2014 Apr; 231(7):1365-75. PubMed ID: 24190587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is emotional intelligence impaired in ecstasy-polydrug users?
    Craig L; Fisk JE; Montgomery C; Murphy PN; Wareing M
    J Psychopharmacol; 2010 Feb; 24(2):221-31. PubMed ID: 18801831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation of factors associated with depressive symptoms among a sample of regular ecstasy consumers.
    Matthews AJ; Bruno R
    Neuropsychobiology; 2010; 61(4):215-22. PubMed ID: 20389132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users.
    Scott RM; Hides L; Allen JS; Lubman DI
    Addict Behav; 2013 Oct; 38(10):2465-72. PubMed ID: 23770644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.
    Milani RM; Parrott AC; Schifano F; Turner JJ
    Hum Psychopharmacol; 2005 Jun; 20(4):249-61. PubMed ID: 15816011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of executive functioning in ecstasy/polydrug users.
    Roberts CA; Jones A; Montgomery C
    Psychol Med; 2016 Jun; 46(8):1581-96. PubMed ID: 26966023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K; Parrott A; Turner J
    J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
    Fisk JE; Montgomery C; Murphy PN
    Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.
    Parrott AC; Sisk E; Turner JJ
    Drug Alcohol Depend; 2000 Jul; 60(1):105-10. PubMed ID: 10821995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.